Mutation Profile of Metastatic Castration-Resistant Prostate Cancer Patients Prior to Olaparib Treatment - EMA vs. FDA

被引：0
|
作者：
Dragos, Vita Setrajcic [1 ]
Stegel, Vida [1 ]
Klancar, Gasper [1 ]
Skerl, Petra [1 ]
Klasinc, Anja Zagozen [1 ]
Novakovic, Srdjan [1 ]
机构：
[1] Inst Oncol Ljubljana, Dept Mol Diagnost, Ljubljana, Slovenia
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2023年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P13.070.D
引用
收藏
页码：548 / 549
页数：2
相关论文
共 50 条
  • [21] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Sugiyama, Takayuki
    Aki, Ryota
    Matsushita, Yuto
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Otsuka, Atsushi
    MEDICAL ONCOLOGY, 2017, 34 (08)
  • [22] Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer
    Maughan, Benjamin L.
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (12) : 1625 - 1632
  • [23] Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
    Chong, Julio T.
    Oh, William K.
    Liaw, Bobby C.
    ONCOTARGETS AND THERAPY, 2018, 11 : 2141 - 2147
  • [24] CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.
    Chen, Gang
    Karzai, Fatima
    Madan, Ravi Amrit
    Cordes, Lisa M.
    Bilusic, Marijo
    Owens, Helen
    Hankin, Amy
    Williams, Monique
    Couvillon, Anna
    Gulley, James L.
    Dahut, William L.
    Thomas, Anish
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Drug approval: Olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer
    Sabouret, Annabelle
    Beuzeboc, Philippe
    BULLETIN DU CANCER, 2023, 110 (04) : 339 - 341
  • [26] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
  • [27] FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 13N - 13N
  • [28] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [29] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [30] New treatment options for patients with metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    CANCER TREATMENT REVIEWS, 2012, 38 (05) : 340 - 345
12345